Bioequivalence and Bioavailability Forum 17:12 CEST

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

Multiple dose study for MR product in EU [Regulatives / Guidelines]

posted by jalgorta - Spain, 2017-03-14 14:18  - Posting: # 17156
Views: 1,070

(edited by Ohlbe on 2017-03-14 17:37)

» For MR products in EMEA, first perform pivotal BE study under fasting state and evaluate the results. If AUC0-t>0.9*AUCinf, you need not to go ahead for steady state BE study. BE under steady state is required when drug accumulates in body. If AUC0-t> 0.9*AUCinf is achieved after signle dose administration, normally, there would not be accumulation.

Hi Samaya, you mention that "first perform pivotal BE under fasting state"... My question is if you can confirm and reference that the calculation must be under fasting. Since in the case of modified release two conditions are necessary, should be fast and/or fed???
Kind regards


Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post! [Ohlbe]

Complete thread:

Back to the forum Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
18,766 posts in 3,998 threads, 1,256 registered users;
online 9 (0 registered, 9 guests [including 6 identified bots]).

Statistics is, or should be, about scientific investigation
and how to do it better, but many statisticians believe
it is a branch of mathematics.    George E.P. Box

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed